Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that it has received clearance for its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA), for F18-Pivalate…
Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’), is pleased to announce a non-binding Letter of Intent (LOI)…
Forward Water Technologies Corp. (TSXV: FWTC) (‘ FWTC ‘) and Fraser Mackenzie Accelerator Corp. (TSXV: FMAC.P) (the ‘ FMAC…
Grande Portage Resources Ltd. (TSXV:GPG)(OTCQB:GPTRF)(FSE:GPB)(‘Grande Portage’ or the ‘Company’) is pleased to report that it has filed an updated…
Description The securities of Elixir Energy Limited (‘EXR’) will be placed in trading halt at the request of EXR,…
Brightstar Resources Limited (ASX: BTR) (Brightstar or the Company) is pleased to announce the second round of non- priority…
Speaking on the sidelines of the Rule Symposium, Brent Cook, founder of Exploration Insights, shared his thoughts on the…
Given that inflation remains an issue for miners, he’s focusing on small gold royalty companies. ‘That’s what I’ve been…
A report published by S&P Global Market Intelligence reveals that the US lags significantly behind other countries in mine…